Evidence map›Paper›PMID 28835477›Full record

ReviewJournal of clinical microbiology2017

Is Staphylococcus lugdunensis Significant in Clinical Samples?

Xavier Argemi, Yves Hansmann, Philippe Riegel, Gilles Prévost

Open access · bronzeAbstract readReview
In one paragraph

Review in Journal of clinical microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 78 citations in OpenAlex.

  1. Emerging microbes & infections · 2026
    Article
  2. Clinical implications of a singleJournal of clinical microbiology · 2026
    Article
  3. Global genomic landscape ofApplied and environmental microbiology · 2026
    Article
  4. Innocent Until Proven Guilty: Native ValveJournal of community hospital internal medicine perspectives · 2026
    Article
  5. Characterization ofBiofilm · 2025
    Article
  6. Review
  7. Study ofInternational journal of molecular sciences · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Frontiers in medicine · 2024
    Article
  13. Case reports in infectious diseases · 2024
    Article
  14. Article
  15. Article
  16. Lugdunin production and activity inMicrobiology spectrum · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Xavier ArgemiHôpitaux Universitaires, Maladies Infectieuses et Tropicales, Strasbourg, France xavier_argemi@hotmail.com.
Yves HansmannHôpitaux Universitaires, Maladies Infectieuses et Tropicales, Strasbourg, France.
Philippe RiegelUniversité de Strasbourg, CHRU de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), VBP EA7290, Institut de Bactériologie, Strasbourg, France.
Gilles PrévostUniversité de Strasbourg, CHRU de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), VBP EA7290, Institut de Bactériologie, Strasbourg, France.
Université de Strasbourg · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The implication of coagulase-negative staphylococci in human diseases is a major issue, particularly in hospital settings wherein these species often act as opportunistic pathogens. In addition, some coagulase-negative staphylococci such as

Indexed as

HumansStaphylococcal InfectionsStaphylococcus lugdunensisVirulence FactorsVirulence Factorsbiofilmendocarditisosteoarticular infectionsproteaseStaphylococcus lugdunensisvirulence

Identifiers

PMID28835477
PMCPMC5654899
OpenAlexW2748672960

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.